Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.6 USD | -0.07% | -4.57% | +24.38% |
Sales 2024 * | 22.15M 27.67M | Sales 2025 * | 36.37M 45.43M | Capitalization | 809M 1.01B |
---|---|---|---|---|---|
Net income 2024 * | -42M -52.47M | Net income 2025 * | -72M -89.94M | EV / Sales 2024 * | 32.4 x |
Net cash position 2024 * | 91.29M 114M | Net cash position 2025 * | 82.95M 104M | EV / Sales 2025 * | 20 x |
P/E ratio 2024 * |
-46.2
x | P/E ratio 2025 * |
-33.2
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Silence Therapeutics plc
1 day | -0.07% | ||
1 week | -4.57% | ||
Current month | +0.02% | ||
1 month | -0.99% | ||
3 months | +13.17% | ||
6 months | +203.44% | ||
Current year | +24.38% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 21-01-05 |
Director of Finance/CFO | 52 | 21-03-31 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-07-28 |
David Lemus
BRD | Director/Board Member | 61 | 18-06-20 |
Iain Ross
CHM | Chairman | 71 | 04-07-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 21.6 | -0.07% | 125,885 |
24-04-25 | 21.62 | -2.92% | 324,153 |
24-04-24 | 22.27 | -1.07% | 109,189 |
24-04-23 | 22.51 | +0.04% | 158,803 |
24-04-22 | 22.5 | -0.62% | 168,397 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- SLN Stock